Helicobacter pylori "rescue" therapy after failure of two eradication treatments

被引:84
作者
Gisbert, JP [1 ]
Pajares, JM [1 ]
机构
[1] Univ Hosp La Princesa, Dept Gastroenterol, Madrid, Spain
关键词
Helicobacter pylori; retreatment; rescue; failure; salvage; third line; rifabutin; levofloxacin; furazolidone;
D O I
10.1111/j.1523-5378.2005.00324.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nowadays, apart from having to know well first-line eradication regimens, we must also be prepared to face Helicobacter pylori treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final-overall-eradication rate. After failure of a combination of proton pump inhibitor (PPI), amoxicillin, and clarithromycin, the use of empirical quadruple therapy (PPI-bismuth-tetracycline-metronidazole), has been generally used as the optimal second-line therapy. Even after two consecutive failures, several studies have demonstrated that H. pylori eradication can finally be achieved in almost all patients if several "rescue" therapies are consecutively given. It seems that performing culture even after a second eradication failure may not be necessary, as it is possible to construct an overall strategy to maximize H. pylori eradication, based on the different possibilities of empirical treatment (when antibiotic susceptibilities are unknown). Thus, if one does not want to perform culture before the administration of the third treatment after failure of the first two, different empirical treatments exist, including regimens based on: 1, amoxicillin (amoxicillin-PPI at high doses); 2, amoxicillin plus tetracycline (PPI-bismuth-tetracycline-amoxicillin, or ranitidine-bismuth-citrate-tetracyline-amoxicillin); 3, rifabutin (rifabutin-amoxicillin-PPI); 4, levofloxacin (levofloxacin-amoxicillin-PPI); and 5, furazolidone (furazolidone-bismuth-tetracycline-PPI).
引用
收藏
页码:363 / 372
页数:10
相关论文
共 71 条
[1]   Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin -: Influence on treatment outcome [J].
Adamek, RJ ;
Suerbaum, S ;
Pfaffenbach, B ;
Opferkuch, W .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) :386-389
[2]   In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657 [J].
Akada, JK ;
Shirai, M ;
Fujii, K ;
Okita, K ;
Nakazawa, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1072-1076
[3]  
Ali' A, 1999, AM J GASTROENTEROL, V94, P2321
[4]  
[Anonymous], 1997, Gastroenterology, V113, pS4
[5]   Treatment of Helicobacter pylori:: an overview [J].
Axon, ATR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 :1-6
[6]   Efficacy of Helicobacter pylori eradication therapies: A single centre observational study [J].
Beales I.L.P. .
BMC Gastroenterology, 1 (1)
[7]   Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment -: Preliminary experience [J].
Bock, H ;
Koop, H ;
Lehn, N ;
Heep, M .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 31 (03) :222-225
[8]   RIFABUTIN - A REVIEW OF ITS ANTIMICROBIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
BROGDEN, RN ;
FITTON, A .
DRUGS, 1994, 47 (06) :983-1009
[9]   High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection [J].
Cammarota, G ;
Martino, A ;
Pirozzi, G ;
Cianci, R ;
Branca, G ;
Nista, EC ;
Cazzato, A ;
Cannizzaro, O ;
Miele, L ;
Grieco, A ;
Gasbarrini, A ;
Gasbarrini, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (07) :789-795
[10]   Rifabutin-based Helicobacter pylori eradication 'rescue therapy' [J].
Canducci, F ;
Ojetti, V ;
Pola, P ;
Gasbarrini, G ;
Gasbarrini, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (01) :143-143